TW202304531A - 放射性配體顯像劑在前列腺癌的用途及注射或輸液用溶液 - Google Patents

放射性配體顯像劑在前列腺癌的用途及注射或輸液用溶液 Download PDF

Info

Publication number
TW202304531A
TW202304531A TW111112920A TW111112920A TW202304531A TW 202304531 A TW202304531 A TW 202304531A TW 111112920 A TW111112920 A TW 111112920A TW 111112920 A TW111112920 A TW 111112920A TW 202304531 A TW202304531 A TW 202304531A
Authority
TW
Taiwan
Prior art keywords
psma
pet
radioligand
imaging agent
imaging
Prior art date
Application number
TW111112920A
Other languages
English (en)
Chinese (zh)
Inventor
安娜 凱特福
伊莉莎白 派瑞拉皮耶拉
貝雷 賀
厄洛熱 培梅根
Original Assignee
法商先進加速器應用公司
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商先進加速器應用公司, 瑞士商諾華公司 filed Critical 法商先進加速器應用公司
Publication of TW202304531A publication Critical patent/TW202304531A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW111112920A 2021-04-02 2022-04-01 放射性配體顯像劑在前列腺癌的用途及注射或輸液用溶液 TW202304531A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21305432 2021-04-02
EP21305432.3 2021-04-02

Publications (1)

Publication Number Publication Date
TW202304531A true TW202304531A (zh) 2023-02-01

Family

ID=75588163

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111112920A TW202304531A (zh) 2021-04-02 2022-04-01 放射性配體顯像劑在前列腺癌的用途及注射或輸液用溶液

Country Status (9)

Country Link
US (1) US20240181092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313175A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514293A (cg-RX-API-DMAC7.html)
KR (1) KR20230165761A (cg-RX-API-DMAC7.html)
CN (1) CN117120100A (cg-RX-API-DMAC7.html)
CA (1) CA3215723A1 (cg-RX-API-DMAC7.html)
IL (1) IL307381A (cg-RX-API-DMAC7.html)
TW (1) TW202304531A (cg-RX-API-DMAC7.html)
WO (1) WO2022207906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
SMT202300035T1 (it) * 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
KR20240027896A (ko) * 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법

Also Published As

Publication number Publication date
CN117120100A (zh) 2023-11-24
JP2024514293A (ja) 2024-04-01
WO2022207906A1 (en) 2022-10-06
IL307381A (en) 2023-11-01
KR20230165761A (ko) 2023-12-05
CA3215723A1 (en) 2022-10-06
EP4313175A1 (en) 2024-02-07
US20240181092A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
Privé et al. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
CA3215723A1 (en) Diagnostic methods of prostate cancer
McCarthy et al. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma
Granov et al. Positron emission tomography
US20250025584A1 (en) Radiopharmaceutical treatment methods and use
US20250269073A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
KR20250044688A (ko) 표적화된 분자 영상화를 위한 구리의 방사성 제약 조성물
Vernekar et al. Radiopharmaceuticals: a new vista for diagnosis and treatment of thyroid cancer
US20250121103A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
US20240042067A1 (en) [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof
US20250032651A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
O'Brien et al. Managing a high-specific-activity iobenguane therapy clinic: from operations to reimbursement
US20260115337A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
AU2018381046A1 (en) Radiolabeled progastrin in cancer diagnosis
WO2026019453A1 (en) [177lu]lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
Elison et al. ANZSNM ASM 2021 POSTER PRESENTATIONS
US20250387523A1 (en) Combination therapy of radionuclide complex
Lou et al. Radioguided Parathyroid Surgery
Bhusari et al. Lu-177-Herceptin: A Potential Radioimmunoconjugate for Treatment of HER2 Metastatic Breast Cancer
Lam Translation and Development of Molecular Imaging Probes for Detecting Response of Breast Cancer to Trastuzumab
US20160193372A1 (en) Methods of identifying surrogate imaging agents for alpha emitter radiopharmaceuticals and their use in treatment of disease